Seres Therapeutics: Will Its Strategic Partnerships & Collaborations Prove to Be a Game-Changing Move?

Seres Therapeutics has outlined significant developments and strategic decisions during its third-quarter 2024 update. The company achieved notable milestones, primarily around its lead clinical candidate, SER-155, and its corporate financial structure, significantly influenced by the sale of its VOWST program to Nestlé Health Science. Below, we discuss the positives, potential challenges, and overall results of these actions. Seres reported positive data from its Phase Ib clinical trial for SER-155, indicating a potential for reducing bacterial bloodstream infections (BSIs) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This data marks a promising development in the clinical validation of Seres’ live biotherapeutics approach. The observed 77% risk reduction in BSIs among treatment groups compared to placebo highlights
SER-155’s therapeutic potential.